Intranasal Cenegermin for Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION)
This study is testing a treatment called cenegermin, given as a nasal spray, for adults with Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION). NAION is a condition that affects your vision. Researchers want to see if cenegermin is safe and effective compared to a vehicle spray (which looks and feels the same but contains no active medicine). You might be able to join if you are 50 to 80 years old, have recently experienced NAION in one eye, and your vision in that eye falls within a specific range. The main goal is to see if participants' vision improves by a certain amount after 24 weeks.
- Study design
- This is a Phase 3, randomized, double-blind study where about 272 participants will be randomly assigned to receive either cenegermin or a vehicle spray. Neither you nor your doctor will know which treatment you are receiving.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- The primary outcome is measured at Week 24, indicating participants will be followed for at least 24 weeks after starting treatment.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Efficacy and Safety of Intranasal Cenegermin in Adult Participants With Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION)
At a glance
Conditions
Where it's being run
18 sites across 12 statesWho to contact
What this trial measures
- Achievement of ≥ 15 letter increase in Best Corrected Visual Acuity (BCVA), assessed in each individual participant, measured using the Early Treatment Diabetic Retinopathy Study (ETDRS) chartBaseline to Week 24
Improvement in visual acuity defined as a \>=15 letter increase in BCVA using ETDRS chart.